Compare KALU & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALU | OPK |
|---|---|---|
| Founded | 1946 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 1.0B |
| IPO Year | 2006 | 2011 |
| Metric | KALU | OPK |
|---|---|---|
| Price | $149.97 | $1.57 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $147.33 | $1.60 |
| AVG Volume (30 Days) | 174.5K | ★ 2.7M |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | ★ 135.89 | N/A |
| EPS | ★ 9.43 | N/A |
| Revenue | ★ $1,585,900,000.00 | $606,879,000.00 |
| Revenue This Year | $13.37 | N/A |
| Revenue Next Year | $2.62 | $4.24 |
| P/E Ratio | $16.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $73.08 | $0.98 |
| 52 Week High | $199.89 | $1.73 |
| Indicator | KALU | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 56.43 |
| Support Level | $116.89 | $1.12 |
| Resistance Level | $150.00 | $1.58 |
| Average True Range (ATR) | 6.04 | 0.07 |
| MACD | -0.45 | -0.00 |
| Stochastic Oscillator | 2.55 | 38.18 |
Kaiser Aluminum Corp specializes in the production of semi-fabricated specialty aluminum mill products, such as aluminum plate and sheet, bare and coated coil and extruded and drawn products, for the end market applications: Aero/HS Products; Packaging; GE Products; and Automotive Extrusions. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.